EURO RX Arzneimittel GmbH
Pharmaceutical Companies · Hannover
EURO RX Arzneimittel GmbH is a pharmaceutical company based in Hannover, Lower Saxony, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
EURO RX Arzneimittel GmbH Address & Contact
EURO RX Arzneimittel GmbH Overview
EURO RX Arzneimittel GmbH in Hannover, Lower Saxony, is a German pharmaceutical company that specializes in the import and distribution of medications in the German market. The company utilizes parallel import opportunities within the European internal market to offer medications at low cost. With a clear focus on quality, safety, and efficiency, EURO RX has established itself as a significant player in the German pharmaceutical sector.
Field of Activity and Products
EURO RX is engaged in the parallel import of medications, sourcing original products from other EU member states where they are available at lower prices, and marketing them in the German market. The key product areas include prescription medications, over-the-counter drugs, as well as specialized therapies that would otherwise be available in Germany only at higher prices. The company holds all necessary import licenses according to German and European pharmaceutical law to ensure the delivery and marketing of its products.
- Prescription Medications: These include drugs for the treatment of chronic diseases such as diabetes, cardiovascular diseases, as well as oncology therapies.
- Over-the-Counter Products: EURO RX offers a selection of OTC products that support patient self-medication.
- Special Approvals: The company also specializes in the procurement of rare medications needed for specific therapy areas that are often difficult to obtain.
Through parallel imports, EURO RX contributes to increased competition and lower drug prices in Germany. This benefits not only retailers but also end consumers who enjoy lower prices for urgently needed medications.
Regulatory Framework
EURO RX Arzneimittel GmbH operates under strict regulatory conditions set forth by the German Medicines Act (AMG) and the European legal framework. The company ensures that all imported medications comply with the quality standards of the European Union, including adherence to Good Distribution Practice (GDP). These regulations guarantee that all delivered products are safe and effective, which is crucial for ensuring patient health and trust.
Location Hannover
Hannover, as the capital city of Lower Saxony, offers favorable conditions for pharmaceutical companies as a business location. The city is home to the Hannover Medical School (MHH) and the Hannover Region Clinic, important medical institutions in Northern Germany. This proximity to leading research institutions and universities not only promotes the exchange between science and industry but also provides access to a qualified labor market. Additionally, Hannover is recognized as a trade fair metropolis, which offers excellent industry contacts and networking opportunities for EURO RX. The annual "CPhI Worldwide" fair attracts leading players from the pharmaceutical sector and serves as an excellent platform for innovations and collaborations.
Particular Strengths and Developments
One of the unique strengths of EURO RX Arzneimittel GmbH is its commitment to sustainability and social responsibility. The company has established various programs to reduce its ecological footprint, including recycling initiatives in packaging. Moreover, EURO RX actively works on projects to support healthcare providers and patients by conducting informative campaigns on topics such as medication therapy safety. The continuous adaptation to new market conditions and regulatory requirements demonstrates the flexibility and innovative strength of the company.
In the coming years, EURO RX plans to further expand its portfolio and invest in digital solutions to optimize access to medications and better meet the needs of patients. This includes the development of a user-friendly platform that facilitates pharmacies and healthcare facilities in placing orders efficiently.
More information: Pharmaceutical companies in Lower Saxony or all pharmaceutical companies in Germany on Sanoliste.
Frequently asked questions about EURO RX Arzneimittel GmbH
What does EURO RX Arzneimittel GmbH do?
EURO RX medicines GmbH is ein medicinesversorger for Spezialmedikamente. Darunder falln Mittel at Krebserkrankung and Autoimmandefiziten. Bei hormonellen Störungen, HIV-Infektionen, Lungenkarzinom, schubförmiger multipler Sklerose or rheumatoide Arthritis. The company gilt als Vorreiter at the Digitalisierung the Lieferkette.
EURO RX Arzneimittel GmbH on social media
More Pharmaceutical Companies in Hannover
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.